Ascendis Pharma (Denmark)
company in Copenhagen, Denmark
ASND Nasdaq
ISIN US04351P1012 SEC CIK 1612042 LEI 549300B66JN3W3J8GH73
Follow Ascendis Pharma (Denmark)
Weekly email: filings, results
Revenue, last quarter
€247.5M
+42.3% vs same quarter last year
Net income
−€33.6M
+12.8% vs same quarter last year
EPS, diluted
-
Operating cash flow
€73.4M
+184.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €720.1M | −€228M |
| FY24 | €363.6M | - |
| FY23 | €266.7M | −€481.4M |
| FY22 | €51.2M | −€583.2M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 86.8% | −18.9% | −31.7% |
| FY24 | 87.8% | −76.7% | - |
| FY23 | 83.4% | −170.8% | −180.5% |
| FY22 | 76.3% | −1097.9% | −1139.6% |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | €17.4M |
| FY24 | - |
| FY23 | €0 |
| FY22 | €105.3M |
- Ascendis Pharma (Denmark)
- Healthcare median
Show the numbers
| Year | Ascendis Pharma (Denmark) | Healthcare median |
|---|---|---|
| FY25 | −31.7% | −30.6% |
| FY24 | - | −47% |
| FY23 | −180.5% | −58% |
| FY22 | −1139.6% | −80.4% |